JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
85 hedge funds and large institutions have $176M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 14 closing their positions.
Holders
85
Holders Change
+2
Holders Change %
+2.41%
% of All Funds
1.95%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
16
Increased
29
Reduced
19
Closed
14
Calls
$3.94M
Puts
$543K
Net Calls
+$3.4M
Net Calls Change
+$2.45M
Top Buyers
| 1 |
1
JPMorgan Chase & Co
New York
|
$2.86M |
| 2 |
BCM
2
Bridgeway Capital Management
Houston,
Texas
|
$1.32M |
| 3 |
3
Man Group
London,
United Kingdom
|
$1.3M |
| 4 |
4
Renaissance Technologies
New York
|
$1.09M |
| 5 |
5
Two Sigma Advisers
New York
|
$1.35M |
